More sensitive technology spurs proteomic and metabolomic biomarker identification, clinical use. (Complete article on page 21)
More sensitive technology spurs proteomic and metabolomic biomarker identification, clinical use. (Complete article on page 21)
Marilyn Matz, Chief Executive Officer and Co-Founder, Paradigm4 “Genomics’ role in the life science vision “is only as credible as its implementation,”
Dr. Zach Pitluk and Dr. Srikant Sarangi on preparing the way for AI/ML to impact drug discovery and development.
Single-cell analysis has great promise… but how can we get there? by Zachary Pitluk